🇺🇸 FDA

Company profile · Sponsor

Nordic

Nordic Group B.V.

E9A03F2 · EMA pharma EU
Pipeline
3
Drugs
0
Patents
0

Quick answer

Nordic (E9A03F2) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 3 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E9A03F2
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (3)

Search pipeline →

  1. Leukine, Lynparza 100 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., Lynparza 150 mg film-coated tablets, UV1

    Nordic

    Ovarian cancer

    phase 2 small molecule active

    1 trial

  2. SODIUM LAURILSULFATE, Canoderm 5 % kräm, Aqua ad iniectabilia Braun Lösungsmittel zur Herstellung von Parenteralia, Propyless 200 mg/g kutan emulsion, Miniderm 20 % kräm, CARBAMIDE, COMBINATIONS

    Nordic

    Atopic dermatitis

    phase 2 small molecule active

    1 trial

  3. Teverelix TFA

    Nordic

    Advanced prostate cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is Nordic?

Nordic (E9A03F2) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 3 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Nordic sponsor?

We track 3 ClinicalTrials.gov-linked programs for Nordic, including Leukine, Lynparza 100 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., Lynparza 150 mg film-coated tablets, UV1 and 2 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Nordic company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.